Interleukin-10, interleukin-6 and interferon-γ gene polymorphisms in melanoma patients

Melanoma Research

Volumn 12, Issue 5, 2002, Pages 465-469

  Martinez Escribano J A ^a   Moya Quiles, M R ^a   Muro, M ^a   Montes Ares, O ^a   Hernandez Caselles T ^a   Frias J F ^a   Alvarez Lopez M R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Cytokine; Interferon ; Interleukin 10; Interleukin 6; Melanoma; Polymorphism

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRON; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; ADULT; AGED; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PROMOTER REGION;

ADULT; AGED; FEMALE; GENOTYPE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; INTRONS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 0036753243     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200209000-00008     Document Type: Article

References (25)

1. Krasagakis K, Garbe C, Orfanos CE. Cytokines in human melanoma cells: Synthesis, autocrine stimulation and regulatory functions. Melanoma Res 1993; 3: 425-433.
2. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio G, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630-637.
3. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T-cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
4. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-760.
5. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis. Clin Cancer Res 1996; 2: 1969-1979.
6. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Am J Pathol 1992; 141: 519-524.
7. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993; 100: 239S-244S.
8. Perrey C, Pravica V, Sinnot PJ, Hutchinson W. Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: A technical report. Transplant Immunol 1998; 6: 193-197.
9. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-60 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
10. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999; 26: 1-3.
11. Higuchi R. Simple and rapid preparation of samples for PCR. In: PCR Technology. Principles and Applications for DNA Amplification. Ehrlich HA (editor). New York: Stockton Press; 1989. pp. 31-38.
12. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19: 239-247.
13. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001; 8: 116-122.
14. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5: 67-68.
15. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2: 1383-1390.
16. Boyano MD, García-Vazquez MD, López-Michelena T, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000; 83: 847-852.
17. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2: 25-31.
18. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific and long-lived immune response against established tumors in mice. J Immunol 1996; 157: 231-238.
19. Chen WF, Zlotnik A. IL-10: A novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528-534.
20. Tsuruma T, Yagihashi A, Torigoe T, Sato N, Kikuchi K, Watanabe N, et al. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells. Cell Immunol 1998; 184: 121-128.
21. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995; 85: 3577-3585.
22. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, et al. Interleukin-10 inhibits tumor metastases through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
23. Lu C, Vickers MF, Kerbel RS. Interlekin 6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992; 89: 9215-9219.
24. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: Correlation with tumor burden. Clin Cancer Res 1996; 2: 1405-1409.
25. Deichmann M, Benner A, Waldmann V, Bock M, Jäckel A, Näher H. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000; 19: 301-307.